Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABENUVA in HIV-1-Infected Adults With Severe Renal Impairment
NCT05601128Phase 3Completed
- Sponsor
- Allegheny Singer Research Institute
- Start
- Jan 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by Allegheny Singer Research Institute. Primary endpoints: Cabotegravir plasma concentration over time (Ctrough), Cabotegravir plasma concentration over time (Cmax) and 6 more. Started Jan 2023; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05601128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05601128.